Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison / Toxina botulínica A (BT-A) versus laser terapia de baixa potência (LLLT) em enxaqueca crônica: Uma triagem comparativa
Arq. neuropsiquiatr
;
76(10): 663-667, Oct. 2018. tab, graf
Article
in English
| LILACS
| ID: biblio-973926
ABSTRACT
ABSTRACT The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders. Methods:
Patients were randomized into two groups BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant.Results:
Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group.Conclusion:
Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.RESUMO
RESUMO O estudo comparou pacientes com cefaleia crônica (CM) tratados com toxina botulínica A (BT-A) versus terapia a laser de baixa intensidade (LLLT), relativos a dias de dor, automedicação, nervosismo e distúrbios do sono. Métodos:
Os pacientes foram randomizados em dois grupos Grupo BT-A (n = 18) e Grupo LLLT (n = 18). Cada paciente preencheu três diários de dor, sendo um antes do início do tratamento (30 dias), durante o tratamento (30 dias) e um após tratamento (30 dias). ANOVA e pós-teste Bonferroni, teste T de Student e análise fatorial foram utilizados e valores de p < 0,05 foram considerados significativos.Resultados:
Ambos os tratamentos foram capazes de reduzir os dias de dor e a ingestão aguda de medicação. Além disso, a ansiedade foi reduzida no grupo BT-A, enquanto que o distúrbio do sono foi reduzido no grupo LLLT.Conclusão:
Nossos resultados mostraram que ambos os tratamentos são eficientes contra CM, sem diferença entre eles.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Botulinum Toxins, Type A
/
Low-Level Light Therapy
/
Acetylcholine Release Inhibitors
/
Migraine Disorders
Type of study:
Controlled clinical trial
/
Screening study
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Arq. neuropsiquiatr
Journal subject:
Neurology
/
Psychiatry
Year:
2018
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Hospital Israelita Albert Einstein/BR
/
Universidade Federal de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS